Recent Announcements
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste®...
Understanding Parkinson’s Fatigue
Introduction Imagine waking up after a full night’s sleep, yet feeling as...
PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships
PhotoPharmics, a clinical-stage medical device company developing...
The Role of Nutrition in Parkinson’s Disease
Introduction Did you know that unintentional weight loss and nutritional...
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in...
Young-Onset Parkinson’s: Navigating Your Journey After an Early Diagnosis
Introduction Receiving a Parkinson's disease diagnosis is a life-altering...
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet...
Understanding and Managing Depression and Anxiety in Parkinson’s
Introduction Did you know that at least 50% of people with Parkinson's Disease...
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join...
Why Am I So Exhausted? Is Fatigue Related to Parkinson’s?
Introduction If you're living with Parkinson's disease (PD), you might have a...
Updates
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste®...
PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships
PhotoPharmics, a clinical-stage medical device company developing...
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in...
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet...
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join...
PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies
New clinical sites open in Illinois, Florida, and Arizona; trial remains open...
PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider
Veteran leaders join to accelerate commercialization and market access...
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Original Press Release Funding supports key milestones as the Pivotal, Phase 3...
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining...